OCT 27·tradingview.comMed
CLPT Q3'26 Earnings: EPS estimate is (0.32) USD
ClearPoint Neuro (CLPT) will report Q3'26 earnings on October 28. Analysts expect revenue of $12.3M and an EPS loss of $0.32. Results will be announced after market close.
StockNASDAQ · US · USDHealthcare · Medical Devices
$CLPT
ClearPoint Neuro, Inc.
ClearPoint Neuro develops and commercializes integrated systems for minimally invasive neurosurgical procedures, and provides services and products for pharmaceutical and biotechnology companies developing brain therapies. Its business has two components: medical devices for neurosurgery and partnerships in biologics and drug delivery. Its products include the ClearPoint system for surgical targeting and navigation, the ClearPoint Prism Neuro Laser Therapy System, and the IRRAflow system for intracranial fluid management in neurocritical care and operating room settings. ClearPoint Neuro also sells the SmartFlow Neuro cannula and provides preclinical studies, clinical trial support, regulatory consultation, device development, and related consulting services. It makes money through sales of devices and disposable components, as well as service fees and partnership arrangements. The company assembles products at its Carlsbad, California facility and manufactures IRRAflow control units at its San Diego, California facility.
Price · $CLPTvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 1
- Bearish
- 0
Insider · 30dAll trades →
No SEC Form 4 filings for $CLPT in the last 30 days.
See all $CLPT insider activity →Top stories · $CLPTMore →
OCT 21·tradingview.com
CLPT Q3'26 Earnings: revenue estimate is 12.30M USD
ClearPoint Neuro (CLPT) will report Q3'26 earnings on October 28, with estimated revenue of $12.30M and EPS of -$0.32. Results will be released after market close.
OCT 14·finanznachrichten.de
ClearPoint Neuro, Inc.: ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026
ClearPoint Neuro (CLPT) will release its Q3 2026 financial results on October 28, 2026, after market close. A live review and conference call will be held at 4:30 p.m. Eastern time. The company offers brain and spine navigation technology and is involved in cell and gene therapy.
CLPT sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CLPT (ClearPoint Neuro, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CLPT coverage spans earnings, financial news and market movers.
What's driving CLPT
The upcoming earnings release could move the stock depending on whether results meet or miss the modest estimates.
Pre‑earnings estimate may set expectations and influence price action when results are released.
The announcement sets a clear date for the earnings release, likely generating pre‑release positioning and post‑release volatility.
ClearPoint Neuro likely faces near‑term sell pressure as its commercial upside from the uniQure partnership is called into question.
Analyst consensus for 2026 shifts lower on both revenue and profitability, with the consensus price target dropping 9.4%.
AlphAI scores every news story that mentions CLPT with an AI model for sentiment and relevance, and aggregates insider trades from ClearPoint Neuro, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $CLPT
Score
CLPT Q3'26 Earnings: EPS estimate is (0.32) USD
ClearPoint Neuro (CLPT) will report Q3'26 earnings on October 28. Analysts expect revenue of $12.3M and an EPS loss of $0.32. Results will be announced after market close.
1 min readCLPT Q3'26 Earnings: revenue estimate is 12.30M USD
ClearPoint Neuro (CLPT) will report Q3'26 earnings on October 28, with estimated revenue of $12.30M and EPS of -$0.32. Results will be released after market close.
1 min readClearPoint Neuro, Inc.: ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026
ClearPoint Neuro (CLPT) will release its Q3 2026 financial results on October 28, 2026, after market close. A live review and conference call will be held at 4:30 p.m. Eastern time. The company offers brain and spine navigation technology and is involved in cell and gene therapy.
2 min readClearPoint Neuro stock tumbles on uniQure trial setback
ClearPoint Neuro (CLPT) shares dropped 24% after partner uniQure (QURE) reported disappointing trial data for its Huntington's disease treatment, AMT-130. The therapy failed to meet primary clinical measures, raising concerns about future revenue for ClearPoint Neuro, which provides delivery hardware and software for the treatment.
2 min readClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported And Analysts Have Been Cutting Their Estimates
ClearPoint Neuro, Inc. (NASDAQ:CLPT) reported Q2 results that missed expectations. According to the article, revenue was $11m, 15% below forecasts, and statutory losses rose 33% to $0.38 per share. For 2026, three analysts’ consensus estimates were cut to $48.9m revenue and $1.32 loss per share, while the consensus price target fell 9.4% to $25.67.
5 min readPowell Industries Posts Downbeat Q3 Results, Joins Clearpoint Neuro, Ichor Holdings And Other Big Stocks
Powell Industries reported Q3 EPS of $1.42, below the $1.47 analyst consensus, and sales of $312.0 million, below the $315.168 million estimate, according to the company. Shares fell 13.4% to $190.02 in pre-market trading. The article also notes Nasdaq 100 futures were up about 150 points.
1 min readClearPoint Neuro Reports Second Quarter 2026 Results
ClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2026 Results Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA, August 3, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a globa
6 min readClearPoint Neuro, Inc.: ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy Designation for Sasineprocel
ClearPoint Neuro (Nasdaq:CLPT) said the FDA granted Aspen Neuroscience RMAT designation for sasineprocel (ANPD001), an investigational autologous dopaminergic neuron cell therapy for Parkinson’s disease. ClearPoint noted its ClearPoint Neuro Navigation System and SmartFlow Cannula were used in Aspen’s ASPIRO trial. RMAT provides expedited FDA interactions but is not FDA approval.
4 min readClearPoint Neuro, Inc.: ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026
ClearPoint Neuro, Inc. (NASDAQ:CLPT) said it will release its 2026 second-quarter results on August 3, 2026 after the market close. The company will host a live conference call the same day at 4:30 p.m. ET, with a replay available until September 2, 2026. No financial figures were provided.
2 min readBURNETT JOSEPH sold $1.1M of CLPT
BURNETT JOSEPH (CEO and President) sold 60,000 shares of ClearPoint Neuro, Inc. (CLPT) at $17.79 ($1.07M total) on 2026-06-17 under a Rule 10b5-1 trading plan.
2 min read